Home » Clinical Trials » Solid tumors » NCT07358260
NCT07358260

A Phase I, Open Label, Dose Escalation, Single Center Study of Autologous B7-H3.CD28Z.CART Cells in Children and Young Adults With Relapsed or Refractory Solid Tumors Expressing B7-H3

Study Summary

The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped responding to standard treatments (relapsed or refractory) and have been identified with a B7-H3 marker. The names of the treatment interventions used in this study are: * B7-H3.CD28Z.CART / B7-H3 CAR T cells * Fludarabine * Cyclophosphamide

Want to learn more about this trial?

Request More Info

Interventions

B7-H3.CD28Z.CARTBIOLOGICAL
Modified autologous T cells administered via Intravenous (IV) infusion
FludarabineDRUG
Administered intravenously
CyclophosphamideDRUG
Administered intravenously

Study Locations

FacilityCityStateCountry
Dana Farber Cancer InstititeBostonMassachusettsUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026